Etentamig clinical trials
Etentamig is named as an intervention in 13 current clinical trials in our USA, Japan, Germany, France, Australia, Israel, UK, Italy, Spain, Canada, Poland, Portugal, Norway, Belgium, Sweden, Denmark, Taiwan, Netherlands, China, Austria, Czechia, Turkey and South Korea registers. 6 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is AbbVie (12). The most-studied condition is Multiple Myeloma. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Etentamig works
All drug targets →- Plasma cell myelomaPhase 3
- Waldenstrom macroglobulinemiaPhase 1/2
- AmyloidosisPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314973, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Etentamig
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Etentamig
13 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Etentamig in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Etentamig. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma
2025-525105-20-00 · Neoplasms
|
Phase 1 | Ongoing | AbbVie Deutschland GmbH & Co. KG | Germany, Poland, Czechia + 6 more |
Conditions studied with Etentamig
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbbVie | 12 |
| Universitätsklinikum Hamburg-Eppendorf | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Etentamig trials
How many clinical trials are testing Etentamig?
13 current trials in our USA, Japan, Germany, France, Australia, Israel, UK, Italy, Spain, Canada, Poland, Portugal, Norway, Belgium, Sweden, Denmark, Taiwan, Netherlands, China, Austria, Czechia, Turkey and South Korea registers name Etentamig (also registered as ABBV-383) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Etentamig trials recruiting patients?
Yes. 6 of the 13 trials are recruiting: 6 with sites in USA, 5 with sites in Japan, 1 with sites in Germany, 5 with sites in France, 4 with sites in Australia, 3 with sites in Israel, 3 with sites in UK, 2 with sites in Italy, 2 with sites in Spain, 2 with sites in Canada, 1 with sites in Poland, 1 with sites in Portugal, 2 with sites in Norway, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Denmark and 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Etentamig clinical trials?
AbbVie (12) and Universitätsklinikum Hamburg-Eppendorf (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Etentamig works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Etentamig works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Etentamig (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.